Colon cancer stem cells: implications for prevention and therapy

Trends in Molecular Medicine

Volumn 14, Issue 11, 2008, Pages 503-509

  Huang, Emina H ^a   Wicha, Max S ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOMATOUS POLYP; CANCER PREVENTION; CANCER STEM CELL; CANCER THERAPY; COLITIS; COLON CANCER; COLON CARCINOGENESIS; COLON POLYPOSIS; CROHN DISEASE; HUMAN; NONHUMAN; PRIMARY TUMOR; REVIEW; ULCERATIVE COLITIS;

ADENOMATOUS POLYPOSIS COLI; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 54249087106     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2008.09.005     Document Type: Review

References (46)

1. Al-Hajj M., and Clarke M.F. Self-renewal and solid tumor stem cells. Oncogene 23 (2004) 7274-7282
2. Wicha M.S., et al. Cancer stem cells: an old idea - a paradigm shift. Cancer Res. 66 (2006) 1883-1890
3. Bhatia M., et al. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 5320-5325
4. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3 (1997) 730-737
5. Kiel M.J., et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121 (2005) 1109-1121
6. Yilmaz O.H., et al. SLAM family markers are conserved among hematopoietic stem cells from old and reconstituted mice and markedly increase their purity. Blood 107 (2006) 924-930
7. Bao S., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006) 756-760
8. Yu F., et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131 (2007) 1109-1123
9. O'Brien C.A., et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445 (2007) 106-110
10. Ricci-Vitiani L., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445 (2007) 111-115
11. Dalerba P., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 10158-10163
12. Todaro M., et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1 (2007) 389-402
13. Ieta K., et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann. Surg. Oncol. 15 (2008) 638-648
14. - metastatic colon cancer cells initiate tumors. J. Clin. Invest. 118 (2008) 2111-2120
15. Min/+ mice attenuates intestinal tumorigenesis. Cancer Res. 68 (2008) 3655-3661
16. + TH1-like responses. J. Clin. Invest. 98 (1996) 1010-1020
17. Berg D.J., et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J. Clin. Invest. 96 (1995) 2339-2347
18. +/- mice. Surgery 139 (2006) 782-788
19. Barker N., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449 (2007) 1003-1007
20. Greaves L.C., et al. Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 714-719
21. Boman B.M., et al. How dysregulated colonic crypt dynamics cause stem cell overpopulation and initiate colon cancer. Cancer Res. 68 (2008) 3304-3313
22. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
23. Powell S.M., et al. APC mutations occur early during colorectal tumorigenesis. Nature 359 (1992) 235-237
24. Bjerknes M. Expansion of mutant stem cell populations in the human colon. J. Theor. Biol. 178 (1996) 381-385
25. Moser A.R., et al. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247 (1990) 322-324
26. Blaser M.J., et al. Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res. 55 (1995) 562-565
27. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
28. Kuper H., et al. Infections as a major preventable cause of human cancer. J. Intern. Med. 248 (2000) 171-183
29. Shacter E., and Weitzman S.A. Chronic inflammation and cancer. Oncology 16 (2002) 217-226 229
30. Loftus Jr. E.V., et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 46 (2000) 336-343
31. Bernstein C.N., et al. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. Lancet 343 (1994) 71-74
32. Eaden J.A., et al. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48 (2001) 526-535
33. Chen R., et al. The initiation of colon cancer in a chronic inflammatory setting. Carcinogenesis 26 (2005) 1513-1519
34. Chen R., et al. DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am. J. Pathol. 162 (2003) 665-672
35. Itzkowitz S.H., and Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 287 (2004) G7-G17
36. Colliver D.W., et al. Molecular profiling of ulcerative colitis-associated neoplastic progression. Exp. Mol. Pathol. 80 (2006) 1-10
37. Krok K.L., and Lichtenstein G.R. Colorectal cancer in inflammatory bowel disease. Curr. Opin. Gastroenterol. 20 (2004) 43-48
38. Jarnerot G., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005) 1805-1811
39. Saha A., et al. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Cancer Res. 67 (2007) 2881-2892
40. de Gramont A., et al. Targeted agents for adjuvant therapy of colon cancer. Semin. Oncol. 33 (2006) S42-S45
41. Diaz-Rubio E. Vascular endothelial growth factor inhibitors in colon cancer. Adv. Exp. Med. Biol. 587 (2006) 251-275
42. Dahan S., et al. Epithelial: lamina propria lymphocyte interactions promote epithelial cell differentiation. Gastroenterology 134 (2008) 192-203
43. Shmelkov S.V., et al. AC133/CD133/Prominin-1. Int. J. Biochem. Cell Biol. 37 (2005) 715-719
44. Jin L., et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12 (2006) 1167-1174
45. Deng G., et al. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 274 (1996) 2057-2059
46. Li L., and Neaves W.B. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 66 (2006) 4553-4557